Clinical Trial Update: A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update examining four dosing regimens of PROCRIT (epoetin alfa) in patients with chronic kidney disease and anemia, plus a protocol adden…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Chronic Kidney Disease, Anemia | Phase 2 | Status: COMPLETED